Osteseconazole: First FDA-approved drug for recurrent vulvovaginal candidiasis
Around 75% of all adult women will have at least 1 yeast infection during their lifetime. About half of them will have a recurrence of the condition and 9% of them may develop recurrent vulvovaginal candidiasis (RVVC).
According to CDC, RVVC is defined as three or more symptomatic acute episodes of yeast infection over one year.
The US Food and Drug Administration has recently approved osteseconazole (Vivjoa) capsules to treat recurrent vulvovaginal candidiasis (RVVC). RVVC is also known as a chronic yeast infection in those women (without reproductive potential) with a history of the condition.
The drug osteseconazole belongs to the azole antifungal drugs, the first and only FDA-approved treatment for RVVC.
According to the studies, the drug showed sustained efficacy in significant long-term reduction of recurrence of the infection through 50 weeks compared with other medications.
In the clinical studies, the most common adverse effects reported with osteseconazole include headache and nausea. The drug is contraindicated in patients with hypersensitivity to the drug oteseconazole and in women of reproductive potential, pregnant, or lactating.
Subscribe to Medicoz Community Youtube Channel for More
Watch Now : LIVE SESSION : 25 Most Important Clinical MCQs in General Surgery | Dr. Sowjanya | Medicoz Community
Watch Now : LIVE SESSION : 25 Most Important Clinical Pathology Question | Dr. Shruthi | Medicoz Community
Watch Now : LIVE SESSION : 25 Top Most Important Clinical PSM Question | Dr. Radhika Kannan | Medicoz Community
View Plans for the NExt Exam Preparations – Click Here
Join us on Instagram for Updates : Medicoz Community
Thank you for Reading .
Leave feedback about this